Back to Search
Start Over
Unexpected Response to Nivolumab in a "Fast Progressor" Head and Neck Cancer Patient.
- Source :
-
Case Reports in Oncology . 2019, Vol. 12 Issue 3, p709-714. 6p. - Publication Year :
- 2019
-
Abstract
- Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R/M-HNSCC, based on improved survival, good toxicity profile, reduction in symptoms and improvement in overall quality of life. This benefit seems to be greater for PD-L1 positive patients and independent of previous treatment, even being observed among heavily pre-treated patients. However, even in responding tumors acquired resistance to nivolumab usually occurred, limiting the drug's activity. We report a case of unexpected prolonged stable disease in second-line treatment with nivolumab after a rapid progression disease under first-line chemotherapy in biomarker-positive R/M-HNSCC. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CANCER patients
*THERAPEUTICS
*SQUAMOUS cell carcinoma
*DISEASE progression
Subjects
Details
- Language :
- English
- ISSN :
- 16626575
- Volume :
- 12
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Case Reports in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 141102829
- Full Text :
- https://doi.org/10.1159/000502858